ERBB2 and breast carcinoma: A retrospective analysis revealed that the combination of pertuzumab and trastuzumab in patients with HER2+ breast cancer brain metastases (BCBM) resulted in significantly extended overall survival, reaching 44 months compared to other groups receiving HER2-targeted therapy or non-targeted therapy (p < 0.001; log-rank test).